DE122009000031I1 - 11 beta-substituierte progesteron-analoge - Google Patents

11 beta-substituierte progesteron-analoge

Info

Publication number
DE122009000031I1
DE122009000031I1 DE122009000031C DE122009000031C DE122009000031I1 DE 122009000031 I1 DE122009000031 I1 DE 122009000031I1 DE 122009000031 C DE122009000031 C DE 122009000031C DE 122009000031 C DE122009000031 C DE 122009000031C DE 122009000031 I1 DE122009000031 I1 DE 122009000031I1
Authority
DE
Germany
Prior art keywords
beta
alkynyl
alkenyl
alkyl
defined above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE122009000031C
Other languages
English (en)
Other versions
DE122009000031I2 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Triangle Institute
Original Assignee
Research Triangle Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Triangle Institute filed Critical Research Triangle Institute
Publication of DE122009000031I1 publication Critical patent/DE122009000031I1/de
Publication of DE122009000031I2 publication Critical patent/DE122009000031I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0052—Nitrogen only at position 16(17)
DE122009000031C 1988-06-23 1989-06-23 11 beta-substituierte progesteron-analoge Active DE122009000031I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/210,503 US4954490A (en) 1988-06-23 1988-06-23 11 β-substituted progesterone analogs
PCT/US1989/002706 WO1989012448A1 (en) 1988-06-23 1989-06-23 11beta-SUBSTITUTED PROGESTERONE ANALOGS

Publications (2)

Publication Number Publication Date
DE122009000031I1 true DE122009000031I1 (de) 2009-11-05
DE122009000031I2 DE122009000031I2 (de) 2011-06-16

Family

ID=22783162

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122009000031C Active DE122009000031I2 (de) 1988-06-23 1989-06-23 11 beta-substituierte progesteron-analoge
DE68927861T Expired - Lifetime DE68927861T2 (de) 1988-06-23 1989-06-23 11 beta-substituierte progesteron-analoge

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE68927861T Expired - Lifetime DE68927861T2 (de) 1988-06-23 1989-06-23 11 beta-substituierte progesteron-analoge

Country Status (13)

Country Link
US (2) US4954490A (de)
EP (1) EP0422100B1 (de)
JP (1) JP2953725B2 (de)
KR (1) KR0161975B1 (de)
AT (1) ATE149839T1 (de)
AU (1) AU635211B2 (de)
CA (1) CA1338906C (de)
DE (2) DE122009000031I2 (de)
DK (1) DK175760B1 (de)
LU (1) LU91575I2 (de)
NL (1) NL300392I2 (de)
NO (2) NO905546L (de)
WO (1) WO1989012448A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3832303A1 (de) * 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE59010853D1 (de) * 1989-08-04 1998-12-03 Schering Ag 11 Beta-Aryl-gona-4,9-dien-3-one
US5041434A (en) * 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
USRE34578E (en) * 1990-05-07 1994-04-05 Lubkin; Virginia Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5407928A (en) * 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
CA2133966C (en) * 1992-04-21 1997-09-09 David A. Sullivan Ocular androgen therapy in sjogren's syndrome
US5536725A (en) * 1993-08-25 1996-07-16 Fmc Corporation Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines
US5639598A (en) * 1994-05-19 1997-06-17 The Trustees Of The University Of Pennsylvania Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions
DE69500542T2 (de) * 1994-05-19 1998-01-02 Akzo Nobel Nv 11,21-Bisphenyl-19-nor-pregnan Derivate
US5780220A (en) * 1994-05-19 1998-07-14 Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting HIV replication
US5929262A (en) * 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
EP2348031B9 (de) * 2000-03-17 2016-08-10 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services 17-Alpha-substituiertes-11-Beta-substituiertes-4-aryl und 21-substituiertes 19-Norpregnadiendionen als Antiprogestationswirkstoffe
JP4499357B2 (ja) * 2001-02-14 2010-07-07 カロ・バイオ・アー・ベー 糖質コルチコイド受容体調節剤
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (de) * 2003-02-28 2010-05-19 Us Gov Health & Human Serv Verfahren zur herstellung von 17 alpha-acetoxy-11 beta-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-dien-3,20-dion, zwischenprodukte dafür, und verfahren zur herstellung dieser zwischenprodukte
US20060247452A1 (en) * 2004-01-21 2006-11-02 Guisasola Luis Octavio S Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
PT1768625E (pt) 2004-07-09 2011-04-18 Hra Pharma Lab Composições de libertação sustida contendo moduladores do receptor da progesterona
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
HU227112B1 (hu) * 2006-06-14 2010-07-28 Richter Gedeon Nyrt Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz
PL2148681T3 (pl) * 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
HU228636B1 (en) * 2007-06-27 2013-04-29 Richter Gedeon Nyrt Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process
ES2626131T3 (es) 2007-10-17 2017-07-24 Laboratoire Hra Pharma Antagonistas del receptor de glucocorticoides tales como mifepristona para tratar el síndrome de Cushing
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
JP5951480B2 (ja) 2009-04-14 2016-07-13 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ オンデマンド避妊方法
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
US8426392B2 (en) 2009-12-09 2013-04-23 Laboratoire Hra-Pharma Method for providing emergency contraception
WO2011091890A1 (en) 2010-02-01 2011-08-04 Laboratoire Hra-Pharma A method for post coital contraception in overweight for obese female subjects using ulipristal acetate
WO2011091892A1 (en) 2010-02-01 2011-08-04 Ulmann Andre A method for late post coital contraception using ulipristal acetate
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
JP5894143B2 (ja) * 2010-03-22 2016-03-23 リプロス セラピューティクス インコーポレイテッド 抗黄体ホルモンの無毒送達のための組成物および方法
PL2576582T3 (pl) 2010-05-26 2020-06-29 Corcept Therapeutics, Inc. Leczenie dystrofii mięśniowej
CN102372760A (zh) * 2010-08-12 2012-03-14 杭州容立医药科技有限公司 一种合成孕酮受体调节剂优力司特的合成方法
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (de) 2010-12-30 2012-07-04 PregLem S.A. Behandlung von Schmerz in Verbindung mit der Dislokation des basalen Endometriums
CN102516345B (zh) 2011-11-01 2014-11-26 上海优拓医药科技有限公司 醋酸乌利司他及其关键中间体的制备方法
EP2545922A1 (de) 2011-07-12 2013-01-16 PregLem S.A. Behandlung von übermäßiger Monatsblutung im Zusammenhang mit Gebärmutterfibromen
CN102344478B (zh) * 2011-07-22 2013-08-07 上海希迈医药科技有限公司 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法
CN102321141B (zh) 2011-07-22 2013-05-15 上海希迈医药科技有限公司 一种17α-乙酰氧基-11β-（4-N,N-二甲氨基苯基）-19-去甲孕甾-4，9-二烯-3,20-二酮的无定形物及其制备方法
CN106046099B (zh) * 2012-01-19 2018-03-16 华润紫竹药业有限公司 甾体化合物及其制备方法和用途
CN104628806A (zh) * 2012-01-19 2015-05-20 华润紫竹药业有限公司 甾体化合物及其制备方法和用途
FR2987271B1 (fr) 2012-02-28 2017-08-18 Hra Pharma Lab Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens
EP2641602A1 (de) 2012-03-23 2013-09-25 PregLem S.A. Verfahren zur Behandlung gynäkologischer Leiden
CN102675395B (zh) * 2012-04-17 2014-04-30 常州市第四制药厂有限公司 醋酸乌利司他的多晶型及其制备方法
KR20150039130A (ko) 2012-05-25 2015-04-09 라보라토이레 에이치알에이 파르마 유방 종양의 예방 및 치료를 위한 울리프리스탈 아세테이트
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
CN102702296B (zh) * 2012-06-19 2014-09-03 山东诚创医药技术开发有限公司 环-3,20-双(1,2-亚乙基缩醛)-17α-羟基-17β-乙酰基-雌甾-5(10),9(11)-二烯-3-酮的制备方法
JP6474722B2 (ja) * 2012-09-28 2019-02-27 あすか製薬株式会社 ウリプリスタール酢酸エステルの結晶多形
JP6200493B2 (ja) 2012-09-28 2017-09-20 あすか製薬株式会社 無定形ウリプリスタール酢酸エステル
CA2885798A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Crystalline polymorphic form of ulipristal acetate
WO2014060888A1 (en) 2012-10-18 2014-04-24 Lupin Limited Novel process and intermediate for preparation of ulipristal
CN103772468B (zh) * 2012-10-19 2017-04-05 华润紫竹药业有限公司 醋酸特拉司酮及其中间体的制备方法和用途
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
FR2997627B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
FR2997628B1 (fr) 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2999081B1 (fr) 2012-12-06 2015-02-27 Hra Pharma Lab Dispersion solide d'un modulateur selectif du recepteur a la progesterone
CN103073612B (zh) * 2013-02-04 2015-11-04 山东大学 醋酸乌利司他关键中间体的制备方法
AR095831A1 (es) 2013-04-10 2015-11-11 Preglem Sa Moduladores de los receptores de progesterona útiles en la terapia de los fibroides uterinos
HU230319B1 (hu) * 2013-10-01 2016-01-28 Richter Gedeon Nyrt. Ipari eljárás szteroid hatóanyagok előállítására
AU2016226451B2 (en) 2015-03-02 2019-12-19 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors
AU2016243625B2 (en) 2015-03-30 2020-09-10 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
EP3335043B1 (de) 2015-08-13 2021-03-31 Corcept Therapeutics, Inc. Verfahren zur differentiellen diagnose des acth-abhängigen cushing-syndroms
CA3011728A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CN105669810B (zh) * 2016-02-19 2017-05-10 常州市第四制药厂有限公司 一种醋酸乌利司他的杂质及其制备和检测方法
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. METHODS OF TREATING NEURO-EPITHELIAL TUMORS USING GLUCOCORTICOID RECEPTOR SELECTIVE MODULATORS
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
CN109053846B (zh) * 2018-08-14 2020-01-07 台州仙琚药业有限公司 制备醋酸优力司特双缩酮的方法
WO2020190351A1 (en) * 2019-03-18 2020-09-24 Nieman Lynnette K Method for improving insulin sensitivity
EP3895692A1 (de) 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Oraler dünnfilm mit glatter schmelzfolie
EP3895691A1 (de) 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristalacetat-otf
CA3205462A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4151204A1 (de) 2021-09-17 2023-03-22 LTS Lohmann Therapie-Systeme AG Schnell zerfallende orale dünne filme/schäume mit hoher wirkstoffbeladung auf basis eines gemisches von polyvinylalkoholen mit unterschiedlichen molekulargewichten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
ES8502612A1 (es) * 1983-06-15 1985-02-01 Schering Ag Procedimiento para la preparacion de 13a-alquilgonanos
FR2586021B1 (fr) * 1985-08-09 1988-10-14 Roussel Uclaf Nouveaux produits derives de la structure 5a-oh d 9(10) 19-nor steroides
IE60780B1 (en) * 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives

Also Published As

Publication number Publication date
LU91575I2 (fr) 2009-08-03
EP0422100A4 (de) 1994-04-27
NO2009014I2 (no) 2009-12-28
NL300392I1 (nl) 2009-08-03
DK175760B1 (da) 2005-02-14
NO905546D0 (no) 1990-12-21
AU635211B2 (en) 1993-03-18
NO2009014I1 (no) 2009-07-06
KR0161975B1 (ko) 1998-11-16
KR900701820A (ko) 1990-12-04
WO1989012448A1 (en) 1989-12-28
EP0422100B1 (de) 1997-03-12
DE122009000031I2 (de) 2011-06-16
US4954490A (en) 1990-09-04
DK305390A (da) 1990-12-21
DK305390D0 (da) 1990-12-21
NO905546L (no) 1990-12-21
DE68927861D1 (de) 1997-04-17
CA1338906C (en) 1997-02-11
DE68927861T2 (de) 1997-10-16
AU3850689A (en) 1990-01-12
NO178264C (de) 1996-02-21
EP0422100A1 (de) 1991-04-17
ATE149839T1 (de) 1997-03-15
NL300392I2 (nl) 2009-10-01
JP2953725B2 (ja) 1999-09-27
NO178264B (de) 1995-11-13
US5073548A (en) 1991-12-17
JPH03505582A (ja) 1991-12-05

Similar Documents

Publication Publication Date Title
DE122009000031I1 (de) 11 beta-substituierte progesteron-analoge
ES2158284T3 (es) Metil-fenil-oxazolidinonas quirales.
FI823923L (fi) Antifibrinolytiskt aktiva foereningar
ES2160171T3 (es) Forma purificada de estreptograminas, su preparacion y las composiciones farmaceuticas que la contienen.
SE8103963L (sv) 10-alkynyl-steroider
GR3005766T3 (de)
AR247744A1 (es) Compuestos organosilano y catalizadores que contienen dichos compuestos
ES2038623T3 (es) Procedimiento para preparar soluciones de oxazafosforinas con estabilidad mejorada.
ATE179169T1 (de) Prostaglandinanaloge
IL119297A (en) 2,3-Dihydroxypropyl-2-(1-oxoalkyl) amino-2-deoxyglucopyranosides a process for their preparation and compositions containing them
DE69431824D1 (de) Verfahren zur Herstellung von Schwefelhaltigen Imidazolderivaten und erhaltene Zwischenprodukte
FI904728A0 (fi) Benzanilider.
NZ231710A (en) Sulphur-containing oxime derivatives and fungicidal compositions
JPS5520735A (en) Cosmetic
IE790031L (en) Fatty acid amides
NZ190862A (en) N-(3-phenylpropyl)-2-hydroxy-2-phenylethlamines pharmaceutical compositions intermediates
SE8103598L (sv) Antiinflammatoriska medel for yttre anvendning
IT1093462B (it) Disposizione di sopporto per il gambo di un rotore di filatura ad esteremita' aperta
PT81690A (de) Neue 13alpha-alkyl-17beta-(3-acyloxypropyl)-gonane
DE69030571D1 (de) Verfahren zur Herstellung von Alkylmethylcarbamaten
IT1245737B (it) Trialchilsilil tetrafluoroetanfosfonati e procedimento per la loro preparazione
JPS53111080A (en) 2-phenyl-4h-1,3-thiazine derivative, its preparation and use
ATE36536T1 (de) Phosphoroimidate.
IT8603380A1 (it) Ventilatore perfezionato per l'areazione di ambienti chiusi